China Resources Double-Crane Pharmaceutical announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd., has received the Drug Registration Certificate for the low-calcium peritoneal dialysis solution (lactate) series of products issued by the National Medical Products Administration. This series of products is suitable for patients with acute and chronic renal failure. Shanghai Changfu started the imitation work in October 2021 and has accumulated R&D investment of 9.6434 million yuan.
华润双鹤：子公司上海长富获低钙腹膜透析液药品注册证书
China Resources Double-Crane Pharmaceutical: Subsidiary Shanghai Changfu Obtains Pharmaceutical Registration Certificate for Low-Calcium Peritoneal Dialysis Fluid.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.